Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME)

This study has been terminated.
Information provided by (Responsible Party):
Transgene Identifier:
First received: June 23, 2011
Last updated: January 4, 2017
Last verified: January 2017